Home » Investors » Board of Directors

Board of Directors

by | Oct 5, 2020

Joshua SilvermanBoard Chairman
Mr. Silverman joined the Company as a Director and Chairman of the Board in August 2016. He is currently the Co–founder and Managing Member of Parkfield Funding LLC, and is a former Principal and Managing Partner of Iroquois Capital Management.

Prior to forming Iroquois, Mr. Silverman served as Co–Chief Investment Officer of Vertical Ventures, LLC, a merchant bank, as well as a Director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as Assistant Press Secretary to The President of The United States.

Mr. Silverman received his B.A. from Lehigh University in 1992. In the past five years, Mr. Silverman has served on the boards of directors of MGT Capital Investments Inc., National Holdings Corporation, Alanco Technologies Inc., Protagenic Therapeutics, Inc. and WPCS International Incorporated
William SingerVice Chairman
Mr. Singer serves as President of the Blanchette Rockefeller Neurosciences Institute (BRNI), where he serves on its Board of Directors and is Chairman of its commercialization committee. For the past three years, he has guided BRNI in the development of its intellectual property for commercial purposes.

In 1980, he became a partner in the Chicago office of Kirkland & Ellis LLP and was a partner for 25 years. He is an of-counsel attorney in the Chicago office of Kirkland & Ellis LLP, and concentrates his practice on corporate, real estate, and legislative matters. He has been listed in Crain’s Who’s Who in Chicago Business 2000, 2001, 2002, 2003, and 2004 editions.

Mr. Singer is a graduate of Brandeis University (BA, 1962) and Columbia University Law School (JD, 1965). Upon graduation from law school, he served as law clerk to the Honorable Hubert Will, U.S. District Court Judge for the Northern District of Illinois.
Alan Tuchman, M.D.Member
Alan Tuchman, MD, MBA (FAAN) is Clinical Professor of Neurology at New York Medical College and the author of over 30 scientific papers and book chapters. He is currently in the private practice of Neurology in Manhattan. He served as Senior Vice President and Chief Medical Officer of Oncolytics Biotech Inc. from 2012-2017 and consults to a number of biotechnology and investment firms. He was as a partner of Xmark Opportunity Partners from 2002 – 2007 and as Executive Chairman of Neurophysics, Inc. from 2003 – 2008. He was the President of the Epilepsy Society of Southern New York from 1992 -1996 as well as Vice Dean for Clinical Affairs at New York Medical College from 1995-1997.

Dr. Tuchman received his MD degree from the University of Cincinnati, College of Medicine, and completed his Neurology Residency at the Mt Sinai School of Medicine. Dr. Tuchman received his MBA from Columbia University.
Daniel Alkon, M.D.Member
Dr. Alkon has served as President and Chief Scientific Officer of Neurotrope since September 2016. A leader in the field, Dr. Alkon comes to Neurotrope after 30 years directing programs on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another 15 years as the Founding Scientific Director of the Blanchette Rockefeller. Neuroscience Institute where he and his team developed neurorestorative therapeutics for degenerative disorders of the central nervous system. He also served as the Toyota Chair of Neurodegenerative Diseases and Professor of Neurology at West Virginia University before joining Neurotrope.

An internationally recognized pioneer in research on brain-based neural networks, the molecular basis of memory, and degenerative brain disorders, he has authored hundreds of scientific articles as well as several books, including Memory Traces in the Brain by Cambridge University Press, and the popular book Memory’s Voice by Harper Collins.

Dr. Alkon received his B.A. from the University of Pennsylvania, and his M.D. at Cornell University, after which he interned at the Mt Sinai Hospital in New York.
Jonathan SchechterDirector
Since 2008, Mr. Schechter has been a Director of Investment Banking at Chardan Capital Markets, LLC where he has helped numerous microcap companies with restructuring of their balance sheets, financing needs and M&A opportunities. From 2005 until 2007, Jonathan acted as the General Counsel for a hedge fund that specialized in PIPE transactions and structured products. He also served on the Board of Directors of DropCar, Inc. Prior to these roles, Jonathan worked as a corporate associate for Bryan Cave LLP specializing in representing investors and investment banks in PIPE transactions. He also represented and advised numerous public companies in all aspects of corporate law.

Mr. Schechter graduated from Duke University in 1995, cum laude, with an AB in political science and graduated from Fordham Law School with a JD. He is licensed to practice law in the State of New York.
George Perry, Ph.D.Board Director
Dr. Perry is dean of the College of Sciences, professor of biology, and holds the Semmes Foundation Distinguished University Chair in Neurobiology at The University of Texas at San Antonio. He is recognized in the field of Alzheimer disease research, where he has studied every aspect of the disease, including amyloidosis, oxidative stress, cytoskeleton, metal homeostasis, cell cycle reentry, and mitochondria. For almost 20 years, Dr. Perry has been a strong advocate for greater diversity in ideas to move the field forward.

He is distinguished as the top Alzheimer’s disease researcher by Expertscape with over 1,000 publications, one of the top 100 most-cited scientists in neuroscience and behavior, and one of the top 25 scientists in free radical research. He is editor for numerous journals and is editor-in-chief for the Journal of Alzheimer’s Disease, the most cited and prolific journal in Alzheimer research. He is a fellow of the American Association for the Advancement of Science, Texas Academy of Science, the Microscopy Society of America, and past-president of the American Association of Neuropathologists.

Dr. Perry obtained his Bachelor of Arts degree in zoology with high honors from University of California, Santa Barbara. After graduation, he headed to Scripps Institution of Oceanography, Hopkins Marine Station and Woods Hole, and obtained his Ph.D. in marine biology. He then received a postdoctoral fellowship in the Department of Cell Biology at Baylor College of Medicine. In 1982, Dr. Perry joined the faculty of Case Western Reserve University, rising to Professor and Interim Chair of Pathology, and currently holds an adjunct appointment.
Bruce BernsteinDirector
Mr. Bernstein has over thirty years of experience in the securities industry, primarily as senior portfolio manager for two alternative finance funds as well as in trading and structuring of arbitrage strategies. Mr. Bernstein has served as President of Rockmore Capital, LLC since 2006, the manager of a direct investment and lending fund with peak assets under management of $140 million. Previously, he served as Co-President of Omicron Capital, LP, an investment firm based in New York, which he joined in 2001. Omicron Capital focused on direct investing and lending to public small cap companies and had peak assets under management of $260 million. Mr. Bernstein started his career at Kidder Peabody, where he rose to the level of Assistant Treasurer. Mr. Bernstein holds a B.B.A. from City University of New York (Baruch).

Investor Contact Information


Synaptogenix, Inc.
1185 Avenue of the Americas,
3rd Floor
New York, NY 10036
(973) 242-0005

Investor Relations

IR Contact
T: 800-811-5591